The association of CH with hematologic malignancy varies according to the disease subtype. (A) Fraction of patients with CH among those who developed each of the hematologic malignancy types listed. We combined MDS and AML into a single therapy-related myeloid neoplasm (t-MN) group because therapy-related MDS behaves aggressively, and molecular characteristics better reflect pathogenesis and prognosis. Lymphoid malignancies are blue and myeloid are red. Total number of cases is presented at the top of each bar. (B) Fraction of patients who had preceding CH among those who developed chronic or acute hematologic malignancies. (C) Cumulative incidence of acute and chronic hematologic malignancies stratified based on the presence or absence of CH. All HRs and P values were calculated using a multivariate competing risk regression, adjusting for age, gender, and cancer type. CLL, chronic lymphocytic leukemia; CML, chronic myeloid leukemia; MPN, myeloproliferative neoplasm; NOS, not otherwise specified. TP53/CK: TP53 mutation and/or complex karyotype.